Search company, investor...

Founded Year



Biz Plan Competition - II | Alive

Total Raised


About RetinAI

RetinAI supports eye care professionals and patients throughout the medical examination process using artificial intelligence (AI). Its solutions rely on advances in medical image analysis, ophthalmology, and machine learning. The company was founded in 2017 and is based in Bern, Switzerland.

Headquarters Location

Freiburgstrasse 3

Bern, 3010,



ESPs containing RetinAI

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The AI eye screening market refers to the adoption of artificial intelligence technologies for the automated screening and detection of various eye conditions and diseases. Using machine learning algorithms and computer vision techniques, AI systems can analyze retinal images or other diagnostic data to identify signs of eye disorders such as diabetic retinopathy, glaucoma, macular degeneration, a…

RetinAI named as Challenger among 10 other companies, including Verily, Digital Diagnostics, and Zilia.

RetinAI's Products & Differentiators

    RetinAI Discovery

    RetinAI Discovery® is a CE-Marked medical image and data management platform with certified AI Models to aggregate data an extracting automatic insights on patient diseases and outcomes. The platform can be configured to connect to PACS or integrate via API calls with the clinic systems. Ophthalmologists in this setting have a single platform that is secure, cloud-based and provides real-time data access. The platform enables participative research and management. Users of the platform can easily share cases with other users granted access, anytime from anywhere.


Research containing RetinAI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned RetinAI in 2 CB Insights research briefs, most recently on Jan 24, 2023.

Expert Collections containing RetinAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RetinAI is included in 2 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,958 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

RetinAI Patents

RetinAI has filed 2 patents.

The 3 most popular patent topics include:

  • computer vision
  • feature detection (computer vision)
  • image processing
patents chart

Application Date

Grant Date


Related Topics




Image processing, Artificial neural networks, Computer vision, Medical imaging, Feature detection (computer vision)


Application Date


Grant Date



Related Topics

Image processing, Artificial neural networks, Computer vision, Medical imaging, Feature detection (computer vision)



Latest RetinAI News

RetinAI Joins Forces with Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium to Forge a Global Retinal Imaging initiative Targeting Research in AMD

Nov 29, 2023

Bern, SWITZERLAND BERN, Switzerland and BOSTON, Nov. 29, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI), announces that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers and industry partners working together to define optimal biomarkers and endpoints in AMD. RIMR members from around the world will now be able to connect through RetinAI’s cloud-based platform, RetinAI Discovery®, to facilitate a frictionless collaboration and derive insights on global AMD datasets, helping to advance research in this disease that is a leading cause of blindness in older individuals. AMD is a significant global health concern, affecting about 170 million individuals and ranking as the third leading cause of vision loss worldwide. The United States alone sees a prevalence of AMD similar to that of all invasive cancers combined, contributing to substantial healthcare costs. The disease burden varies by region, as illustrated by studies showing differences in AMD prevalence between Western countries and China, and among ethnic groups globally. As a member of the RIMR consortium, RetinAI will leverage its innovative digital health technologies as a technology backbone to support RIMR’s international network of leading experts in AMD to aggregate and analyze, at-scale, research and real-world clinical and imaging data. The result will be the generation of a highly diverse database and analysis using AI to help address leading research questions of AMD, such as differences among ethnic groups. “By being a member of RIMR, we are setting the foundation to connect leading AMD experts from around the world to help advance their important biomarker-led research,” states Dr. Carlos Ciller, CEO of RetinAI. “We are thrilled to be a part of the consortium and help to facilitate cutting-edge research with a shared goal of improving patient care,” he added. “We’re excited about working with RetinAI as a member of the consortium,” said Dr. SriniVas Sadda, Executive Committee Chair for RIMR, Director of the AI Laboratory at Doheny Eye Institute, and Professor David Geffen, School of Medicine at UCLA. “RetinAI’s focus on digital health technologies and connectivity in Ophthalmology will enable us to build a highly diverse database in AMD, providing the enriched insights to advance our understanding of AMD to drive our goal for finding a cure in AMD.” About RetinAI Medical AG and Ikerian AG Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc., develop software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. About RetinAI Discovery® RetinAI Discovery® ("Discovery") is a software platform to enable the right decisions sooner based on evidence, AI-derived insights, automation & data. Discovery is a modular and certified (FDA - 510(K) / CE - MDR) medical image & data platform that digests data, works via the web browser in the cloud, enables precision analysis with proprietary AI models and transfer of medical data linked to the patient, connecting devices, data sources & decisions in a seamless and secure manner. Discovery is the workbench for healthcare professionals throughout the entire journey of the disease, facilitating decisions for better patient care. About the AMD Imaging Consortium Joining forces with academic centers and industry partners, Ryan Initiative for Macular Research (RIMR) AMD Imaging Consortium has been launched. This non-profit consortium will work to define optimal biomarkers and endpoints to facilitate the design of the studies to identify treatments for Age-related Macular Degeneration (AMD) before it causes permanent damage. The RIMR AMD Imaging Consortium is creating a cloud-based, GDPR-compliant, anonymized database that aggregates data on a large scale from various sources, such as clinical trials, epidemiological studies, registries, and institutions worldwide. Advanced AI technology will allow analysis across this highly diverse database. This will help answer complex research questions, such as understanding differences in AMD among various ethnic groups. For further information please contact: At the company

RetinAI Frequently Asked Questions (FAQ)

  • When was RetinAI founded?

    RetinAI was founded in 2017.

  • Where is RetinAI's headquarters?

    RetinAI's headquarters is located at Freiburgstrasse 3, Bern.

  • What is RetinAI's latest funding round?

    RetinAI's latest funding round is Biz Plan Competition - II.

  • How much did RetinAI raise?

    RetinAI raised a total of $2.74M.

  • Who are the investors of RetinAI?

    Investors of RetinAI include IMD Startup Competition, b2venture, Verve Ventures, Eurostars Programme and Venture Kick.

  • Who are RetinAI's competitors?

    Competitors of RetinAI include Nocturne and 8 more.

  • What products does RetinAI offer?

    RetinAI's products include RetinAI Discovery.

  • Who are RetinAI's customers?

    Customers of RetinAI include Novartis.


Compare RetinAI to Competitors

Eyenuk Logo

Eyenuk is a global artificial intelligence (AI) medical technology and services company, focusing on AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. The company offers products that autonomously analyze patient's retinal images, detect signs of disease, and return an easy-to-read report, primarily targeting the healthcare industry. It was founded in 2010 and is based in Woodland Hills, California.


Viderai provides retinal analysis using artificial intelligence to patients. It offers products that help specialists diagnose patients with diseases such as diabetic retinopathy and its primary clients are ophthalmologists and public healthcare insurance companies. The company was founded in 2019 and is based in Ostrava, Czech Republic.

Digital Diagnostics Logo
Digital Diagnostics

Digital Diagnostics operates as an artificial intelligence (AI) based diagnostic healthcare technology company. It offers LumineticsCore, DermSpot, DermTriage, and more for eye and skin diseases. The company was formerly known as IDx Technologies. It was founded in 2010 and is based in Coralville, Iowa.

Intelligent Retinal Imaging Systems

Intelligent Retinal Imaging Systems is a company focused on the early detection of retinal pathologies, particularly in the healthcare sector. The company offers a cloud-based, camera-agnostic solution that aids healthcare providers in prioritizing diabetic eye care, by providing retinal screening software that helps capture, enhance, and diagnose diabetic retinopathy. The company primarily serves the healthcare industry, including health risk assessment companies, payors, and healthcare providers. It was founded in 2012 and is based in Pensacola, Florida.

Remidio Logo

Remidio develops a range of ophthalmic products. The company's flagship product is a portable fundus camera, used to detect and diagnose eye conditions such as diabetic retinopathy and glaucoma. It also offers solutions such as portable eye health screening, digital documentation, telemedicine platforms, and more. It was founded in 2009 and is based in Bengaluru, India.


AmberFlux is a software company that focuses on artificial intelligence and edge computing within the Industry 4.0 and Healthcare sectors. The company offers a platform that enables efficient deployment and management of AI at the edge, using a patented dynamic, self-learning system for data analysis and implementation of actions. This platform primarily caters to businesses in the digital technology and healthcare industries. It was founded in 2020 and is based in Hyderabad, India.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.